Skip to main content

Cardiovascular risks of chemo-immunotherapy for lung cancer: A population-based cohort study

Chan, Jeffrey Shi Kai, Tang, Pias, Ng, Kenrick, Dee, Edward Christopher, Lee, Teddy Tai Loy, Chou, Oscar Hou In, Lee, Yan Hiu Athena, Lau, Dawnie Ho Hei, Liu, Tong, Tse, Gary and others. (2022) Cardiovascular risks of chemo-immunotherapy for lung cancer: A population-based cohort study. Lung Cancer, 174 . pp. 67-70. ISSN 1872-8332. (doi:10.1016/j.lungcan.2022.10.010) (KAR id:98146)

Abstract

Despite their proven efficacy for treating lung cancer, the cardiovascular risks associated with programmed cell death protein 1 (PD-1) inhibitors and their combinations with chemotherapy (chemo-immunotherapy) are unclear. This study aimed to investigate these associations. This retrospective cohort study included Hong Kong patients with lung cancer receiving PD-1 inhibitors during 2013-2021. Patients with non-concurrent use of PD-1 inhibitors and chemotherapy, any use of tyrosine kinase inhibitors or other immunotherapy agents, and those with prior stroke, heart failure, or myocardial infarction were excluded. PD-1 inhibitors and chemo-immunotherapy were compared for major adverse cardiovascular events (MACE), a composite of cardiovascular mortality, heart failure, stroke, and myocardial infarction. All patients were followed up until the end of 2021. Inverse probability of treatment weighting was used to balance covariates between the two treatment groups. In total, 713 patients (333 PD-1 inhibitors users and 380 chemo-immunotherapy users) were analysed. Over a mean follow-up of 1.4 ± 1.3 years, 24 had MACE, with an observed incidence of 2.8 [1.6-4.8] events per 100 person-year for patients on PD-1 inhibitors, and 2.1 [1.2-3.8] per 100 person-year for patients on chemo-immunotherapy. No significant between-group difference in MACE incidence was observed (log-rank p = 0.641). The cardiovascular risks associated with PD-1 inhibitors and chemo-immunotherapy may not be significantly different amongst patients with lung cancer. Cardiovascular events associated with either regimen may be uncommon.

Item Type: Article
DOI/Identification number: 10.1016/j.lungcan.2022.10.010
Additional information: ** From PubMed via Jisc Publications Router ** History: received 20-06-2022; revised 01-10-2022; accepted 24-10-2022.
Uncontrolled keywords: Lung cancer, PD-1, Immunotherapy, Cardio-oncology, Cohort, Chemotherapy
Subjects: R Medicine
Divisions: Divisions > Division of Natural Sciences > Medway School of Pharmacy
SWORD Depositor: JISC Publications Router
Depositing User: JISC Publications Router
Date Deposited: 24 Nov 2022 12:08 UTC
Last Modified: 25 Nov 2022 10:35 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/98146 (The current URI for this page, for reference purposes)

University of Kent Author Information

  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.